Chemotherapy Induced Peripheral Neuropathy Treatment Market 2025

Chemotherapy Induced Peripheral Neuropathy Treatment Market Size

The global chemotherapy induced peripheral neuropathy treatment market reached a value of nearly $1,650.0 million in 2024, having grown at a compound annual growth rate (CAGR) of 5.24% since 2019. The market is expected to grow from $1,650.0 million in 2024 to $2,225.75 million in 2029 at a rate of 6.17%. The market is then expected to grow at a CAGR of 5.81% from 2029 and reach $2,951.26 million in 2034. Growth in the historic period resulted from increasing prevalence of cancer, rising number of clinical trials and rising adoption of pain management therapies. Factors that negatively affected growth in the historic period were the high treatment costs and healthcare reimbursement challenges. Going forward, supportive government initiatives and funding, expansion of chemotherapy usage, growing awareness among oncologists and patients and improved cancer survival rates support will drive growth. Factor that could hinder the growth of the chemotherapy induced peripheral neuropathy treatment market in the future include were limited FDA-approved drugs impact of trade war and tariff and regulatory uncertainty.

Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers

The key drivers of the chemotherapy induced peripheral neuropathy treatment market include: Expansion Of Chemotherapy Usage During the forecast period, the expansion of chemotherapy usage is expected to propel the growth of the CIPN treatment market. Chemotherapy drugs are essential in cancer treatment, but many of these agents induce peripheral neuropathy as an adverse effect. As the use of chemotherapy expands—driven by increasing cancer incidence and broader treatment protocols—the prevalence of patients experiencing CIPN correspondingly rises. The expanding patient population with CIPN symptoms such as numbness, tingling and pain in the extremities creates a substantial demand for effective therapeutic interventions. With more patients experiencing CIPN, healthcare providers are more alert to the condition and diagnose it more often. This leads to higher use of treatments specifically targeting CIPN. The expansion of chemotherapy usage growth contribution during the forecast period in 2024 is 1.50%.

Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints

The key restraints on the chemotherapy induced peripheral neuropathy treatment market include: Limited FDA-Approved Drugs The limited FDA-approved drugs are expected to restrict the growth of the CIPN treatment market, during the forecast period. The limited number of FDA-approved drugs specifically for CIPN restricts treatment options for patients and physicians, thereby constraining the overall growth. This scarcity leads to a heavy reliance on off-label use of medications designed for other conditions, which can impact treatment effectiveness and patient confidence. As a result, market growth for CIPN-specific therapies remains subdued. Additionally, pharmaceutical companies may be cautious about investing in new CIPN treatments due to regulatory challenges and uncertain market acceptance, slowing innovation and hindering the expansion of this therapeutic segment. Growth affected by limited FDA-approved drugs during the forecast period in 2024 is -2.18%.

Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends

Major trends shaping the chemotherapy induced peripheral neuropathy treatment market include: Collaborative Research Enhances Understanding Of Chemotherapy-Induced Peripheral Neuropathy Major companies operating in the CIPN treatment market are adopting collaborative research initiative approach to develop advanced solutions. Strategic partnerships help CIPN treatment companies by combining resources and expertise, enhancing research and development capabilities, expanding market reach and accelerating commercialization, ultimately driving innovation and growth in the CIPN treatment industry. For instance, in July 2025, University of Dundee, a UK-based research university partnered with Eli Lilly and Company, a US-based pharmaceutical company and Versus Arthritis, a UK-based charity focused on supporting individuals with arthritis and musculoskeletal conditions to successfully complete the research phase of the PAINSTORM Dundee Chemotherapy-Induced Peripheral Neuropathy (CIPN) Study. This collaborative effort focused on understanding the causes and progression of CIPN in cancer patients undergoing neurotoxic chemotherapy. The study involved around 200 participants, employing a multifaceted approach that includes quantitative sensory testing, blood biomarker analysis and optional magnetic resonance imaging (MRI) scans. The research aims to identify genetic, clinical and psychosocial risk factors contributing to CIPN, with the ultimate goal of informing personalized prevention and treatment strategies. Advances In Selective FABP5 Inhibitors For Chemotherapy-Induced Peripheral Neuropathy A growing trend in the CIPN treatment market is the increased interest in this indication, supported by new guidance from the U.S. Food and Drug Administration (FDA) on clinical trial design CIPN. For instance, in July 2024, Artelo Biosciences, Inc., a US-based clinical-stage pharmaceutical company announced that the FDA had approved its Investigational New Drug (IND) application for ART26.12, for the treatment of CIPN. ART26.12 is a selective inhibitor of fatty acid binding protein 5 (FABP5), which enhances endocannabinoid levels to help alleviate neuropathic pain. ART26.12 specifically showed efficacy in models of oxaliplatin-induced peripheral neuropathy; a common form of CIPN. The preclinical data suggests that ART26.12 may reduce nerve damage and improve pain management for patients undergoing chemotherapy. This development marks a significant step forward in addressing the unmet medical need for effective CIPN treatments. Artelo Biosciences continues to advance ART26.12 towards clinical trials to confirm its safety and efficacy in humans.

Opportunities And Recommendations In The Chemotherapy Induced Peripheral Neuropathy Treatment Market

Opportunities – The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by drug class will arise in the neurotransmitter based therapy segment, which will gain $1,752.88 million of global annual sales by 2029. The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by treatment will arise in the medication segment, which will gain $1,880.52 million of global annual sales by 2029. The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by drug type will arise in the generic segment, which will gain $2,080.74 million of global annual sales by 2029. The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by distribution channel will arise in the hospital pharmacy segment, which will gain $1,167.72 million of global annual sales by 2029. The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by end-user will arise in the hospitals segment, which will gain $1,376.49 million of global annual sales by 2029. The chemotherapy induced peripheral neuropathy treatment market size will gain the most in the USA at $104.33 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the chemotherapy induced peripheral neuropathy treatment to focus on leveraging regulatory advances to accelerate CIPN treatment development, focus on strategic investment to advance novel CIPN therapies, focus on expanding in the fastest-growing CIPN treatment segment, focus on expanding medication segment to drive CIPN market growth, focus on expanding branded drug segment to capture high growth in CIPN market, expand in emerging markets, focus on strategic collaborations to accelerate innovation and market growth, focus on competitive and value-based pricing strategies, focus on educational and multichannel promotion, focus on collaboration and KOL engagement, focus on expanding online pharmacy segment for CIPN treatment distribution and focus on specialty clinics to capture high growth in CIPN treatment market.